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104 Antibiotic use in years preceding chronic lung infection with
multiresistant Pseudomonas aeruginosa
F. Vermeulen1, M. Proesmans1, L. Dupont1, K. De Boeck1. 1University Hospital
of Leuven, Leuven, Belgium
Intensive treatment of lung infection is standard CF care. We explored whether
antibiotic (AB) use in Pseudomonas aeruginosa (Pa) colonized patients drives
infection with multiresistant Pa (MRPa).
In 241 patients born after 1980 bacteriologic data plus AB use between 1995 and
2010 were analysed retrospectively. Chronic Pa infection was deﬁned according to
the Leeds criteria. Pa isolates resistant to all the AB of at least 2 classes were
considered MR. Days on AB per year were counted in patients with chronic Pa
infection who did and did not become infected with MRPa.
163 patients never acquired chronic Pa infection. 11 had chronic MRPa infection
from onset, 35 had chronic Pa throughout, 32 had MRPa after chronic Pa. Yearly
AB use during chronic Pa infection was analyzed in 25 subjects with chronic Pa and
in 24 before onset of MRPa. Median days on IV AB per year was higher pre MRPa
(43.2 days, IQR 30.0–62.4) than in patients never becoming MRPa (29.8 days,
IQR 10.1–45.4), (p = 0.05). No difference was noted in use of oral AB (median
45.6 days IQR 24.4–68.7 vs 30.5 days IQR 20.5–124.9, p = 0.54) and inhaled AB
(median 248.3 days IQR 168.5–365.0 vs 320.7 days IQR 208.5–353.7, p = 0.45).
The proportion of patients who ever used azithromycin was not different (11/24
vs 7/25, p = 0.15). More patients with MRPa had siblings with CF (14/24 vs 3/25,
p = 0.02). Median number of years of AB use, age and FEV1 at last year of analysis
were not signiﬁcantly different.
A quarter of patients have MRPa from onset of chronic Pa infection. In the other
MRPa subjects the yearly burden of AB use and having a sibling with CF were
related to the development of MRPa infection.
105 Antibiotic dosing strategies of colistin on bioﬁlm
growing Pseudomonas aeruginosa: pharmacokinetic and
pharmacodynamic issues
H. Wang1, H. Wu1, O. Ciofu2, Z. Song1, N. Høiby1,2. 1University Hospital
of Copenhagen, Department of Clinical Microbiology, Copenhagen, Denmark;
2University of Copenhagen, Institute for International Health, Immunology and
Microbiology, Copenhagen, Denmark
The purpose of this study was to optimize the dosing strategies of colistin on
the bioﬁlm infections of P. aeruginosa. Killing curves of colistin on bioﬁlms of
non-mucoid and mucoid strains were made on Days 1, 3 and 7. The microtiter
plate method was used to test minimal inhibitory concentration (MIC) and minimal
bactericidal concentration (MBC) for planktonic bacteria, and the minimal bioﬁlm
inhibitory concentration (MBIC) and minimal bioﬁlm eradication concentration
(MBEC) were done on Days 1, 3 and 7. Pharmacokinetics (PK) and pharmaco-
dynamics (PD) study was performed in a lung infection model of neutropenic
mouse. Colistin showed concentration-dependent killing activity for bioﬁlms of
non-mucoid, and mucoid P. aeruginosa on Days 1, 3 and 7. The MBIC was 4−8-
fold higher than the MIC, and the MBEC was 8−16-fold higher than the MBC of
planktonic cells. The maximum bactericidal effect of colistin was attained at 2−12 h
in bioﬁlm-grown compared to 1−4 h in planktonic cells. MBIC and MBEC on Day 3
and Day 7 were higher than those on Day 1. The time of drug concentration exceeds
MBEC (T>MBEC) was 0 when colistin was administrated systemically with the
dose of 16mg/kg. MBIC and MBEC of colistin were much higher than the MIC
and MBC. The MBIC and MBEC of colistin increased with the age of the bioﬁlm.
Higher doses and longer treatment time of colistin were required for eradication
of bioﬁlm compared with the planktonic P. aeruginosa. The PK/PD indices of
fAUC/MBIC and fAUC/MBEC are probably applied best for colistin in bioﬁlms.
Aggressive and early treatment of antibiotics and combined antibiotic therapy are
highly recommended for bioﬁlm eradication in CF patients.
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Objectives: Clarithromycin (CLA) is used to treat CF patients and is metabolised
in the liver by the enzyme CYP3A4. The Erythromycin Breath Test (ERMBT)
measures CYP3A4 activity in vivo and may be used to identify patients needing
larger doses of an antibiotic to avoid treatment failure. We investigated the
correlation between CYP3A4 activity and the metabolism of CLA.
Methods: We included 22 CF patients (21−53 yr) with chronic lung infections.
ERMBT: 0.15MBq [14C-N-methyl] erythromycin i.v. were given. Every 10min for
1 h the patients expired in a glass with 4ml hyamine liquid collecting the exhaled
CO2. The
14C activity was measured using liquid scintillation. 500mg CLA was
given orally and blood samples were collected every half hour for 3 h and at 6 and
12 h. The concentration of CLA and the metabolite 14-hydroxyCLA were measured
by HPLC, and AUC, Tmax and Cmax were calculated.
Results: We found a 10-fold variation in AUC for CLA, median 881 ug/ml·min,
a 12-fold variation in AUC for 14-hydroxyCLA median 366 ug/ml·min, a 16-fold
variation in Cmax for CLA median 3.4 ug/ml and a 11-fold variation in Cmax for
14-hydroxyCLA median 0.9 ug/ml.
We found 8-fold variation in the CYP3A4 (ERMBT %14C/h), median 0.8. A linear
correlation between the CYP3A4 activity and the metabolism of CLA expressed as
the CLA/14-hydroxyCLA ratio was demonstrated (P< 0.05).
Conclusion: The large variation in the pharmacokinetic proﬁle of CLA in CF
patients may cause treatment failure. Similar problems may involve other antibiotics,
which are metabolised by CYP3A4. ERMBT can be used to indentify CF patients
who may be in risk of developing therapeutic failure or drug toxicity.
107 In vitro susceptibility of Pseudomonas aeruginosa (PA) does not
predict clinical response to aztreonam 75mg powder and solvent
for nebuliser solution (AZLI): a responder analysis in subjects
with cystic ﬁbrosis (CF)
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Objective: Due to high achievable sputum concentrations of inhaled antibiotics, the
utility of MICs to predict clinical response is not established. We conducted a ret-
rospective responder analysis of CF subjects enrolled in a Phase 3 randomized trial
of AZLI vs. tobramycin nebuliser solution (TNS) based on PA isolate susceptibility.
Methods: Data from subjects with CF and chronic PA infection treated with
3 intermittent 28-day courses of 75mg AZLI (TID) or 300mg TNS (BID) in
a 6-month trial (ClinicalTrials.gov NCT00757237) were analyzed. Subjects were
categorized by the MIC of their least susceptible PA isolate to aztreonam or
tobramycin at the start of the 3rd course. Subjects were deﬁned as improved if FEV1
% predicted increased by 6% or as worsened if FEV1% predicted decreased by
4% within the 3rd course. Data for subjects with no change is not presented.
Results: Comparing AZLI subjects with PA aztreonam MIC <128mg/L vs.
128mg/L, 52% vs. 43% improved while 20% vs. 21% worsened, respectively.
No differences were observed in AZLI subjects with PA aztreonam MIC <64mg/L
vs. 64mg/L; ~50% improved and ~20% worsened. Comparing TNS subjects
with PA tobramycin MIC <16mg/L vs. 16mg/L, 31% vs. 22% improved while
40% vs. 52% worsened, respectively. No differences were observed in TNS subjects
with PA tobramycin MIC <4mg/L vs. 4mg/L; ~30% improved and ~45%
worsened.
Conclusions: PA susceptibility to either aztreonam or tobramycin was not predictive
of clinical response in CF patients receiving multiple courses of therapy.
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